A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer

NCT04179864 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

102

Enrollment

INDUSTRY

Sponsor class

Stopped The study was terminated early as Sponsor decided to discontinue the development of tazemetostat in metastatic castration resistant prostate cancer and the primary endpoint was not met for this study. There were no safety concerns.

Conditions

Metastatic Prostate Cancer
Metastatic Castration-resistant Prostate Cancer

Interventions

DRUG: Tazemetostat
DRUG: Abiraterone/prednisone
DRUG: Enzalutamide

Sponsor

Epizyme, Inc.